Kedrion S.p.A.
Clinical trials sponsored by Kedrion S.p.A., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New IVIg therapy aims to boost platelets in chronic ITP patients Results expected Dec 2026 (estimated)
- New antibody therapy aims to shield kids with rare immune disease from deadly infections Results expected Dec 2026 (estimated)
-
New IVIg therapy aims to boost platelets in chronic ITP patients
Disease control Recruiting nowThis study tests a medicine called KIg 10 (intravenous immunoglobulin) in adults with chronic ITP, a condition where the immune system destroys platelets, causing bleeding and bruising. The goal is to see if KIg 10 can safely raise platelet counts and stop bleeding. About 40 peop…
Phase 3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for nerve disease: immune therapy trial targets long-term control
Disease control Recruiting nowThis study tests two different doses of an intravenous immune globulin (IGIV 10%) as maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. About 161 participants will receive either a higher o…
Phase 3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC